Differential Cytotoxic Activity of a Novel Palladium-Based Compound on Prostate Cell Lines, Primary Prostate Epithelial Cells and Prostate Stem Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ulukaya, Engin ^a   Frame, Fiona M ^b   Cevatemre, Buse ^a   Pellacani, Davide ^b   Walker, Hannah ^b   Mann, Vincent M ^c   Simms, Matthew S ^d   Stower, Michael J ^e   Yilmaz, Veysel T ^a   Maitland, Norman J ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

^d HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^e YORK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PALLADIUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE STEM CELL; STEM CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DNA DAMAGE; EPITHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; NEOPLASTIC STEM CELLS; PALLADIUM; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84877633486     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064278     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA: a cancer journal for clinicians 60: 277-300.
3. Jones JS, (2011) Radiorecurrent Prostate Cancer: An Emerging and Largely Mismanaged Epidemic. European Urology 60: 411-412.
4. Kirby M, Hirst C, Crawford ED, (2011) Characterising the castration-resistant prostate cancer population: a systematic review. International journal of clinical practice 65: 1180-1192.
5. Schroder F, Crawford ED, Axcrona K, Payne H, Keane TE, (2012) Androgen deprivation therapy: past, present and future. BJU international 109Suppl 6: 1-12.
6. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews Cancer 8: 755-768.
7. Rau T, van Eldik R, (1996) Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Metal ions in biological systems 32: 339-378.
8. Graham RD, Williams DR, (1979) The synthesis and screening for anti-bacterial,-cancer,-fungicidal and-viral activities of some complexes of palladium and nickel Journal of Inorganic and Nuclear Chemistry. 41: 1245-1249.
9. Abu-Surrah AS, Al-Sa'doni HH, Abdalla MY, (2008) Palladium-based chemotherapeutic agents: Routes toward complexes with good antitumor activity. Cancer Therapy 6: 1-10.
10. Al-Masoudi NA, Abdullah BH, Essa AH, Loddo R, LaColla P, (2010) Platinum and palladium-triazole complexes as highly potential antitumor agents. Archiv der Pharmazie 343: 222-227.
11. Budzisz E, Krajewska U, Rozalski M, (2004) Cytotoxic and proapoptotic effects of new Pd(II) and Pt(II)-complexes with 3-ethanimidoyl-2-methoxy-2H-1,2-benzoxaphosphinin-4-ol-2-oxide. Polish journal of pharmacology 56: 473-478.
12. Divsalar A, Saboury AA, Mansoori-Torshizi H, Ahmad F, (2010) Design, synthesis, and biological evaluation of a new palladium(II) complex: beta-lactoglobulin and K562 as targets. The journal of physical chemistry B 114: 3639-3647.
13. Eryazici I, Moorefield CN, Newkome GR, (2008) Square-planar Pd(II), Pt(II), and Au(III) terpyridine complexes: their syntheses, physical properties, supramolecular constructs, and biomedical activities. Chemical reviews 108: 1834-1895.
14. Ruiz J, Villa MD, Cutillas N, Lopez G, de Haro C, et al. (2008) Palladium(II) and platinum(II) organometallic complexes with 4,7-dihydro-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine. Antitumor activity of the platinum compounds. Inorganic chemistry 47: 4490-4505.
15. Tamasi G, Casolaro M, Magnani A, Sega A, Chiasserini L, et al. (2010) New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. Journal of inorganic biochemistry 104: 799-814.
16. Tusek-Bozic L, Furlani A, Scarcia V, De Clercq E, Balzarini J, (1998) Spectroscopic and biological properties of palladium(II) complexes of ethyl 2-quinolylmethylphosphonate. Journal of inorganic biochemistry 72: 201-210.
17. Dodoff NI, Kubiak M, Kuduk-Jaworska J, Mastalarz A, Kochel A, et al. (2009) Structure, NMR Spectra and Cytotoxic Effect of Palladium(II) and Platinum(II) Complexes of Glyoxylic Acid Oxime. Chemija 20: 208-217.
18. Nadeem S, Bolte M, Ahmad S, Fazeelat T, Tirmizi SA, et al. (2010) Synthesis, crystal structures and, antibacterial and antiproliferative activities in vitro of palladium(II) complexes of triphenylphosphine and thioamides. Inorganica Chimica Acta 363: 3261-3269.
19. Khan H, Badshah A, Murtaz G, Said M, Rehman ZU, et al. (2011) Synthesis, characterization and anticancer studies of mixed ligand dithiocarbamate palladium(II) complexes. European journal of medicinal chemistry 46: 4071-4077.
20. Mukherjee S, Chowdhury S, Chattapadhyay AP, Bhattacharya A, (2011) Spectroscopic, cytotoxic and DFT studies of a luminescent palladium(II) complex of a hydrazone ligand that induces apoptosis in human prostate cancer cells Inorganica Chimica Acta. 373: 40-46.
21. Valentini A, Conforti F, Crispini A, De Martino A, Condello R, et al. (2009) Synthesis, oxidant properties, and antitumoral effects of a heteroleptic palladium(II) complex of curcumin on human prostate cancer cells. Journal of medicinal chemistry 52: 484-491.
22. Cummings SD, (2009) Platinum complexes of terpyridine: Interaction and reactivity with biomolecules. Coordination Chemistry Reviews 253: 1495-1516.
23. Guney E, Yilmaz VT, Sengul A, Buyukgungor O, (2010) Platinum(II) and palladium(II) saccharinato complexes with 2,2′:6′,2″-terpyridine: Synthesis, characterization, crystal structures, photoluminescence and thermal studies. Inorganica Chimica Acta 363: 438-448.
24. Ulukaya E, Ari F, Dimas K, Sarimahmut M, Guney E, et al. (2011) Cell death-inducing effect of novel palladium(II) and platinum(II) complexes on non-small cell lung cancer cells in vitro. Journal of cancer research and clinical oncology 137: 1425-1434.
25. Ulukaya E, Ari F, Dimas K, Ikitimur EI, Guney E, et al. (2011) Anti-cancer activity of a novel palladium(II) complex on human breast cancer cells in vitro and in vivo. European journal of medicinal chemistry 46: 4957-4963.
26. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer research 65: 10946-10951.
27. Chen G, Shu J, Stacey DW, (1997) Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide. Oncogene 15: 1643-1651.
28. Barth S, Glick D, Macleod KF, (2010) Autophagy: assays and artifacts. The Journal of pathology 221: 117-124.
29. Mizushima N, Yoshimori T, (2007) How to interpret LC3 immunoblotting. Autophagy 3: 542-545.
30. Guney E, Yilmaz VT, Ari F, Buyukgungor O, Ulukaya E, (2011) Synthesis, characterization, structures and cytotoxic activity of palladium(II) and platinum(II) complexes containing bis(2-pyridylmethyl)amine and saccharinate. Polyhedron 30: 114-122.
31. Pelaez MA, Ramirez T, Martinez M, Sharma P, Alvarez C, et al. (2004) Synthesis, Crystal Structures and Anticancer Activity of the New Chiral Mono- and Dinuclear Palladium(II) Complexes derived from (S)-(-)-(1-phenylethylimino)benzylphenylketone. Zeitschrift für anorganische und allgemeine Chemie 630: 1489-1494.
32. Frame FM, Maitland NJ, (2011) Cancer stem cells, models of study and implications of therapy resistance mechanisms. Advances in experimental medicine and biology 720: 105-118.
33. Maitland NJ, Collins AT, (2010) Cancer stem cells- A therapeutic target? Current Opinion in Molecular Therapeutics 12: 662-673.
34. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular cancer 5: 67.
35. Brabec V, Kasparkova J, (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 8: 131-146.
36. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175.
37. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G, (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nature reviews Molecular cell biology 8: 741-752.
38. Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, et al. (2012) The autophagic paradox in cancer therapy. Oncogene 31: 939-953.
39. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. The Journal of clinical investigation 119: 1109-1123.
40. Helgason GV, Karvela M, Holyoake TL, (2011) Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 118: 2035-2043.
41. Lefranc F, Facchini V, Kiss R, (2007) Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. The oncologist 12: 1395-1403.
42. Ogier-Denis E, Codogno P, (2003) Autophagy: a barrier or an adaptive response to cancer. Biochimica et biophysica acta 1603: 113-128.
43. Gozuacik D, Kimchi A, (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891-2906.
44. Kaini RR, Hu CA, (2012) Synergistic killing effect of chloroquine and androgen deprivation in LNCaP cells. Biochemical and biophysical research communications 425: 150-156.
45. Yang ZJ, Chee CE, Huang S, Sinicrope FA, (2011) The role of autophagy in cancer: therapeutic implications. Molecular cancer therapeutics 10: 1533-1541.
46. Sharrard RM, Maitland NJ, (2007) Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines. Cellular signalling 19: 129-138.
47. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, et al. (2008) Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 21: 1451-1460.
48. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J, (2008) Is PTEN loss associated with clinical outcome measures in human prostate cancer? British journal of cancer 99: 1296-1301.
49. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, et al. (1995) Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In vitro cellular & developmental biology Animal 31: 14-24.
50. Maitland NJ, Macintosh CA, Hall J, Sharrard M, Quinn G, et al. (2001) In vitro models to study cellular differentiation and function in human prostate cancers. Radiation research 155: 133-142.